# Candidate 1 Decision Use Case

## Use-case standard

The candidate cannot rely on a purely statistical claim. A cause-allocation error matters only if different causes imply different actions, utilities, or escalation choices. Competing-risk clinical prediction literature explicitly motivates reporting event-of-interest, competing-event, and all-cause risks together; Mozumder et al. give cardiotoxic cancer treatment as an example where cardiovascular and cancer mortality can matter simultaneously.[1]

## Abstract action model

Let actions be `d0`, `d1`, and `d2`, where `d1` preferentially reduces loss from cause 1 and `d2` preferentially reduces loss from cause 2. Define expected loss `L(d,J,t)` and choose `d*(x)=argmin_d E[L(d,J,T)|X=x]`. Fixed total risk does not fix the expected loss when actions weight causes differently.

This is a valid decision-theoretic preflight, but it is not a clinical recommendation.

## Strongest verified real context

The best verified context is competing mortality in oncology: cancer mortality versus cardiovascular or other-cause mortality can have different implications for treatment-risk assessment and follow-up. Mozumder et al. explicitly use cardiotoxic cancer treatment as motivation for understanding the partition of total mortality risk.[1]

This establishes **conditional decision relevance**, not a validated intervention policy. No treatment threshold, utility, or patient-level action rule was frozen in Step 00.

## Decision-reversal result

The elementary vector example reverses the abstract preferred action while preserving all-cause risk. This proves possibility, not prevalence, clinical magnitude, or superiority over decision-curve analysis.

Status: **ELEMENTARY**.

## Existing decision-analysis threat

Competing-risk decision-analysis work already studies how risks and benefits should be weighed in the presence of competing risks.[5] Therefore, “cause-specific risk affects decisions” is not a new claim. A surviving project would need a precise transport/regret result that changes external-validation practice.

## Gate assessment

Decision-Relevance Gate: **CONDITIONAL**. The oncology use case is credible and source-supported, but no real action rule or compatible multi-site dataset was verified. It cannot support a PASS by itself.

Sources consulted: [1][2][3]. Additional sources: [4][5][6]. Dataset sources: [7][8]. Comparator sources: [9][10].

## Sources

[1] https://europepmc.org/api/getPdf?pmcid=PMC12519608 — Mozumder et al. 2025 full text
[2] https://www.bmj.com/content/377/bmj-2021-069249 — van Geloven et al. 2022
[3] https://link.springer.com/article/10.1186/s41512-021-00114-6 — Austin et al. 2022 calibration curves
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC10946485 — Temporal recalibration
[5] https://pmc.ncbi.nlm.nih.gov/articles/PMC11521377 — Competing-risk decision analysis
[6] https://seer.cancer.gov/data — SEER data
[7] https://seer.cancer.gov/data/access.html — SEER access
[8] https://physionet.org/content/mimiciv/3.1 — MIMIC-IV
[9] https://proceedings.mlr.press/v209/jeanselme23a/jeanselme23a.pdf — Neural Fine-Gray
[10] https://proceedings.mlr.press/v193/hu22a.html — Distributionally robust survival
